Cargando…

Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center

BACKGROUND: Rectal gastrointestinal stromal tumor (GIST) is a rare digestive disease that has a distinct malignant tendency compared to that of gastric-derived GIST. At present, there is still no standard, and the surgical approach to rectal GIST is controversial. METHODS: The clinicopathological da...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zifeng, Guo, Wentai, Huang, Rongkang, Hu, Minhui, Wang, Huaiming, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154442/
https://www.ncbi.nlm.nih.gov/pubmed/32309348
http://dx.doi.org/10.21037/atm.2020.01.55
_version_ 1783521818561216512
author Yang, Zifeng
Guo, Wentai
Huang, Rongkang
Hu, Minhui
Wang, Huaiming
Wang, Hui
author_facet Yang, Zifeng
Guo, Wentai
Huang, Rongkang
Hu, Minhui
Wang, Huaiming
Wang, Hui
author_sort Yang, Zifeng
collection PubMed
description BACKGROUND: Rectal gastrointestinal stromal tumor (GIST) is a rare digestive disease that has a distinct malignant tendency compared to that of gastric-derived GIST. At present, there is still no standard, and the surgical approach to rectal GIST is controversial. METHODS: The clinicopathological data and prognosis of rectal GIST patients admitted to the Sixth Affiliated Hospital of Sun Yat-sen University from 1998.01.01 to 2018.12.31 were collected retrospectively. All cases were divided into either the transanal (TA) group or the nontransanal (NTA) group. RESULTS: A total of 537 GIST cases were treated in 10 years, including 82 rectal GIST cases (64 cases underwent surgical resection, including 29 cases in the TA group and 35 cases in the NTA group). Preoperative neoadjuvant therapy (P=0.003), postoperative adjuvant therapy (P=0.017), operative time (P=0.013), blood loss (P=0.038), anus-preserver (P=0.048), 30-day complication rate (P=0.000), time to flatus (P=0.036), hospital stays (P=0.011), distance from the anus (P=0.047), tumor size (P=0.002), mitotic count (P=0.035) and National Institutes of Health (NIH) criteria (P=0.000) were significantly different between these two groups (all P<0.05). The median follow-up time was 41 (range, 1–122) months. Twelve patients had recurrence and metastasis, and 4 patients died. The 5-year disease-free survival (DFS) and overall survival (OS) were 74.4% and 91.2%, respectively, in the whole group. There were no statistically significant differences between the TA group and the NTA group at 5-year DFS (81.3% vs. 79.0%, P=0.243) and OS (88.7% vs. 93.3%, P=0.308). CONCLUSIONS: In the treatment of rectal GIST, TA resection has a minimally invasive effect, less postoperative complications, high anal sphincter preservation rate, and R0 resection rate and a better prognosis. How to improve the proportion of neoadjuvant therapy and choose the appropriate cases for TA surgery is still a challenge.
format Online
Article
Text
id pubmed-7154442
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-71544422020-04-17 Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center Yang, Zifeng Guo, Wentai Huang, Rongkang Hu, Minhui Wang, Huaiming Wang, Hui Ann Transl Med Original Article BACKGROUND: Rectal gastrointestinal stromal tumor (GIST) is a rare digestive disease that has a distinct malignant tendency compared to that of gastric-derived GIST. At present, there is still no standard, and the surgical approach to rectal GIST is controversial. METHODS: The clinicopathological data and prognosis of rectal GIST patients admitted to the Sixth Affiliated Hospital of Sun Yat-sen University from 1998.01.01 to 2018.12.31 were collected retrospectively. All cases were divided into either the transanal (TA) group or the nontransanal (NTA) group. RESULTS: A total of 537 GIST cases were treated in 10 years, including 82 rectal GIST cases (64 cases underwent surgical resection, including 29 cases in the TA group and 35 cases in the NTA group). Preoperative neoadjuvant therapy (P=0.003), postoperative adjuvant therapy (P=0.017), operative time (P=0.013), blood loss (P=0.038), anus-preserver (P=0.048), 30-day complication rate (P=0.000), time to flatus (P=0.036), hospital stays (P=0.011), distance from the anus (P=0.047), tumor size (P=0.002), mitotic count (P=0.035) and National Institutes of Health (NIH) criteria (P=0.000) were significantly different between these two groups (all P<0.05). The median follow-up time was 41 (range, 1–122) months. Twelve patients had recurrence and metastasis, and 4 patients died. The 5-year disease-free survival (DFS) and overall survival (OS) were 74.4% and 91.2%, respectively, in the whole group. There were no statistically significant differences between the TA group and the NTA group at 5-year DFS (81.3% vs. 79.0%, P=0.243) and OS (88.7% vs. 93.3%, P=0.308). CONCLUSIONS: In the treatment of rectal GIST, TA resection has a minimally invasive effect, less postoperative complications, high anal sphincter preservation rate, and R0 resection rate and a better prognosis. How to improve the proportion of neoadjuvant therapy and choose the appropriate cases for TA surgery is still a challenge. AME Publishing Company 2020-03 /pmc/articles/PMC7154442/ /pubmed/32309348 http://dx.doi.org/10.21037/atm.2020.01.55 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yang, Zifeng
Guo, Wentai
Huang, Rongkang
Hu, Minhui
Wang, Huaiming
Wang, Hui
Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center
title Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center
title_full Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center
title_fullStr Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center
title_full_unstemmed Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center
title_short Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center
title_sort transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154442/
https://www.ncbi.nlm.nih.gov/pubmed/32309348
http://dx.doi.org/10.21037/atm.2020.01.55
work_keys_str_mv AT yangzifeng transanalversusnontransanalsurgeryforthetreatmentofprimaryrectalgastrointestinalstromaltumorsa10yearexperienceinahighvolumecenter
AT guowentai transanalversusnontransanalsurgeryforthetreatmentofprimaryrectalgastrointestinalstromaltumorsa10yearexperienceinahighvolumecenter
AT huangrongkang transanalversusnontransanalsurgeryforthetreatmentofprimaryrectalgastrointestinalstromaltumorsa10yearexperienceinahighvolumecenter
AT huminhui transanalversusnontransanalsurgeryforthetreatmentofprimaryrectalgastrointestinalstromaltumorsa10yearexperienceinahighvolumecenter
AT wanghuaiming transanalversusnontransanalsurgeryforthetreatmentofprimaryrectalgastrointestinalstromaltumorsa10yearexperienceinahighvolumecenter
AT wanghui transanalversusnontransanalsurgeryforthetreatmentofprimaryrectalgastrointestinalstromaltumorsa10yearexperienceinahighvolumecenter